{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:51:55Z","timestamp":1786978315315,"version":"build-2736575974"},"reference-count":30,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2014,7,3]],"date-time":"2014-07-03T00:00:00Z","timestamp":1404345600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2014,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      To describe the suspected medications, types of reactions, and outcomes of adverse events (\n                      <jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>\n                      s) most commonly reported to the United States Food and Drug Administration (\n                      <jats:styled-content style=\"fixed-case\">FDA<\/jats:styled-content>\n                      ) in children by age group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      All case reports submitted to the\n                      <jats:styled-content style=\"fixed-case\">FDA<\/jats:styled-content>\n                      Adverse Event Reporting System (\n                      <jats:styled-content style=\"fixed-case\">FAERS<\/jats:styled-content>\n                      ) between January 1, 2007, and August 27, 2012, for children (1 to &lt;\u00a012\u00a0yrs) and adolescents (12 to &lt;\u00a018\u00a0yrs) were examined. The most commonly reported suspected drugs were ranked. The corresponding\n                      <jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>\n                      s with serious outcome were compared and described between age groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We identified a total of 78,623 reports in the\n                      <jats:styled-content style=\"fixed-case\">FAERS<\/jats:styled-content>\n                      database (53.8% in children and 46.2% in adolescents). Serious outcomes were noted in 40% of the children and 43% of the adolescents. The proportion of all case reports for central nervous system stimulants (lisdexamfetamine, 69.8%; methylphenidate, 68.0%) and analgesics (ibuprofen, 72.3%; acetaminophen, 68.6%) was higher in children, whereas tumor necrosis factor blockers (infliximab, 78.2%; adalimumab, 77.1%), atypical antipsychotics (aripiprazole 52.7%; risperidone 58.3%; quetiapine 72.1%) and oral contraceptives (levonogrestrel, 99.2%; drospirenone and ethinyl estradiol, 97.9%) were more commonly reported in adolescents. For most drugs, the types of reactions reported were similar but had different rank order across age groups, with the most dissimilar profiles being observed for isotretinoin and aripiprazole.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      This study highlights high\u2010risk medications and their\n                      <jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>\n                      profiles in children and adolescents. Our findings underscore the need for further confirmation of particular drug and\n                      <jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>\n                      pairs and the heterogeneity of\n                      <jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>\n                      s by age.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/phar.1455","type":"journal-article","created":{"date-parts":[[2014,7,3]],"date-time":"2014-07-03T04:29:02Z","timestamp":1404361742000},"page":"918-926","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Drugs Associated with Adverse Events in Children and Adolescents"],"prefix":"10.1002","volume":"34","author":[{"given":"Wan\u2010Ju","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Pharmacy Systems, Outcomes and Policy College of Pharmacy University of Illinois at Chicago Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd A.","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Systems, Outcomes and Policy College of Pharmacy University of Illinois at Chicago Chicago Illinois"},{"name":"Center for Pharmacoepidemiology and Pharmacoeconomic Research College of Pharmacy University of Illinois at Chicago Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Simon","family":"Pickard","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Systems, Outcomes and Policy College of Pharmacy University of Illinois at Chicago Chicago Illinois"},{"name":"Center for Pharmacoepidemiology and Pharmacoeconomic Research College of Pharmacy University of Illinois at Chicago Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel N.","family":"Caskey","sequence":"additional","affiliation":[{"name":"Internal Medicine and Pediatrics College of Medicine University of Illinois at Chicago Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glen T.","family":"Schumock","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Systems, Outcomes and Policy College of Pharmacy University of Illinois at Chicago Chicago Illinois"},{"name":"Center for Pharmacoepidemiology and Pharmacoeconomic Research College of Pharmacy University of Illinois at Chicago Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,7,3]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"World Health Organization.Promoting Safety of Medicinces For Children.2007. Available fromhttp:\/\/www.who.int\/medicines\/publications\/essentialmedicines\/Promotion_safe_med_childrens.pdf. Accessed March 3 2014."},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.16.2114"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02600255"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/906570"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199223010-00001"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.104.S3.585"},{"key":"e_1_2_9_8_1","first-page":"411","volume-title":"Basic and therapeutic aspects of perinatal pharmacology","author":"Wilson JT","year":"1975"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2002.t01-3-01689.x"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200427130-00006"},{"key":"e_1_2_9_11_1","unstructured":"U.S. Food and Drug Administration.Title V in Best Pharmaceuticals for Children Act of 2007. Available fromhttp:\/\/www.fda.gov\/downloads\/Drugs\/DevelopmentApprovalProcess\/DevelopmentResources\/UCM049870.pdf. Accessed March 3 2014."},{"key":"e_1_2_9_12_1","volume-title":"Safe and effective medicines for children: pediatric studies conducted under the best pharmaceuticals for children act and the pediatric research equity act","author":"National Research Council","year":"2012"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.290.7.905"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.10.1266"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2013.465"},{"key":"e_1_2_9_16_1","unstructured":"U.S. Food and Drug Administration.FDA Adverse Event Reporting System (FAERS). Available fromhttp:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Surveillance\/AdverseDrugEffects\/default.htm. Accessed March 3 2014."},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1679"},{"key":"e_1_2_9_18_1","unstructured":"U.S. Food and Drug Administration.Drugs@FDA. Available fromhttp:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/. Accessed March 3 2014."},{"key":"e_1_2_9_19_1","unstructured":"U.S. Census Bureau Population Division.National population estimates of the older population by age group sex and race\/Hispanic status. Available fromhttp:\/\/www.census.gov\/popest\/. Accessed March 3 2014."},{"key":"e_1_2_9_20_1","unstructured":"U.S. Food and Drug Administration.Breakdown of FDAAA Completed Pediatric Studies. Available fromhttp:\/\/www.fda.gov\/Drugs\/DevelopmentApprovalProcess\/DevelopmentResources\/ucm190622.htm. Accessed March 3 2014."},{"key":"e_1_2_9_21_1","unstructured":"U.S. Food and Drug Administration.Pediatric Exclusivity Granted. Available fromhttp:\/\/www.fda.gov\/Drugs\/DevelopmentApprovalProcess\/DevelopmentResources\/ucm050005.htm. Accessed March 3 2014."},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.04113.x"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.2165\/11587540-000000000-00000"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2013.09.001"},{"key":"e_1_2_9_25_1","unstructured":"U.S. Food and Drug Administration.FDA Asks Attention\u2010Deficit Hyperactivity Disorder (ADHD) Drug Manufacturers to Develop Patient Medication GuidesAvailable fromhttp:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm107918.htm. Accessed March 28 2014."},{"key":"e_1_2_9_26_1","unstructured":"European Medicines Agency.European Medicines Agency makes recommendations for safer use of Ritalin and other methylphenidate\u2010containing medicines in the EU. Available fromhttp:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Press_release\/2009\/11\/WC500014589.pdf. Accessed on March 28 2014."},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-2546"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.6.696"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(99)00301-0"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.110.5.e53"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.387"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.1455","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.1455","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.1455","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T17:18:51Z","timestamp":1761067131000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.1455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,3]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["10.1002\/phar.1455"],"URL":"https:\/\/doi.org\/10.1002\/phar.1455","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,3]]},"assertion":[{"value":"2014-07-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}